Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.76 |
| ▸ | KIT | P10721 | 15/20 | 0.76 |
| ▸ | FLT3 | P36888 | 15/20 | 0.76 |
| ▸ | CSF1R | P07333 | 8/20 | 0.76 |
| ▸ | FLT1 | P17948 | 8/20 | 0.76 |
| ▸ | FLT4 | P35916 | 7/20 | 0.76 |
| ▸ | LYN | P07948 | 6/20 | 0.76 |
| ▸ | BLK | P51451 | 6/20 | 0.76 |
| ▸ | SRC | P12931 | 5/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.76 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.76 |
| ▸ | AURKA | O14965 | 3/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.76 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.76 |
| ▸ | ABL1 | P00519 | 2/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.76 |
| ▸ | LTK | P29376 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421656 | 0.94 | KDR (0.79) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL425738 | 0.91 | AURKB (0.76) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL425370 | 0.91 | KDR (0.74) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL421031 | 0.90 | KDR (0.73) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL419956 | 0.89 | KDR (0.75) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL419587 | 0.87 | KDR (0.71) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL423744 | 0.87 | KDR (0.68) | KDRKITFLT3CSF1RFLT1 | |
| SCHEMBL422466 | 0.87 | AURKB (0.72) | KDRKITFLT3CSF1RFLT1 | |
| Linifanib SCHEMBL29375368 | 0.86 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 | |
| Linifanib SCHEMBL93804 | 0.86 | KDR (1.00) | KDRKITFLT3CSF1RFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | claimed |
| JP-4810427-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1638941-B1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LAB (US) | 2010-06-02 | — | — | EP | claimed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | claimed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | claimed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | claimed |
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8642776-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8299243-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2246333-B1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2009050291-A2 | SOLID DISPERSION PRODUCT OF N-ARYL UREA-BASED DRUGS | ABBOTT GMBH & CO. KG (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KDR 724/4885KIT 361/4885FLT3 41/4885 |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KDR 724/4885KIT 361/4885FLT3 41/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | KDR 724/4885KIT 361/4885FLT3 41/4885 |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KDR 724/4885KIT 361/4885FLT3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.